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Abstract
Background To establish the prognostic and discrimina-
tive value of the pro-atrial natriuretic peptide (pro-ANP)
level in patients with severe sepsis or septic shock.
Patients and methods An observational and prospective
study was conducted on 50 critically ill patients with severe
sepsis or septic shock. Measurements of the level of pro-
calcitonin (PCT) and mid-regional pro-ANP were deter-
mined in the serum of patients with commercially available
immunoluminometric tests.
Results The median pro-ANP level was signiﬁcantly
higher in non-survivors than in survivors (P\0.05) on all
consecutive days. No signiﬁcant differences in the pro-
ANP levels were observed in patients with severe sepsis
and septic shock. There was a strong correlation between
the PCT and pro-ANP levels on admission in non-survivors
and in septic shock patients (r = 0.56, P = 0.007 and
r = 0.43, P = 0.02, respectively).
Conclusions pro-ANP evaluated in severe sepsis and
septic shock patients is a valuable prognostic biomarker,
but, in contrast to PCT, which is routinely used as a
diagnostic marker of severe sepsis and septic shock, it does
not possess diagnostic and discriminative value.
Keywords Pro-atrial natriuretic peptide (pro-ANP) 
Procalcitonin (PCT)  Severe sepsis  Septic shock
Introduction
Immune inﬂammatory reactions, which are responses to
infection,are essential tothe body’s protective mechanisms.
The often excessive and uncontrolled course of such reac-
tions is one of the crucial factors inﬂuencing multiple organ
dysfunction syndrome (MODS), which impacts intensive
careunit(ICU)patientmortality.Accordingtothedeﬁnition
from 1992 [1], there are three clinical forms of response to
infection: sepsis, severe sepsis, and septic shock. They are
differentiated by the presence and degree of the intensity of
cardiovascular dysfunction resulting from the extensity of
the inﬂammatory response [2]. Severe sepsis is deﬁned as
sepsis with one or more organ dysfunctions or tissue hypo-
perfusion [3]. Septic shock is characterized by the most
advancedformofcirculatorysystemfailure,andisdeﬁnedas
severe sepsis with persisting hypotension, despite adequate
ﬂuidresuscitationorbloodlactateconcentrationC4 mmol/L
[3].Thepathophysiologyofseveresepsisandsepticshockat
the cellular level is associated with an advanced form of
microcirculatory and mitochondrial distress syndrome
(MMDS). It involves endothelium dysfunction with apop-
tosis and coagulation disturbances, resulting in global tissue
hypoxia[4,5].Atrialnatriureticpeptide(ANP),consistingof
28 amino acids, is a peptide hormone and a member of the
natriuretic peptide family. Its conservative part is composed
of 17 amino acids that form a ring structure with disulﬁde
bonds and determine the biological features of ANP. ANP
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DOI 10.1007/s15010-011-0235-0with a half-life of 3–4 min is cleared out rapidly from the
circulation. pro-ANP, composed of 126 amino acids, is the
precursor of ANP and is the primary form of storing ANP in
atrial cardiomyocytes. The N-terminal part of pro-ANP
(1–98) has a longer half-life (60–120 min) than ANP. ANP
possesses diuretic and natriuretic properties, resulting from
the direct inhibition of sodium absorption in the renal col-
lecting duct. ANP decreases blood pressure, modulates
endothelium permeability, and has an effect on the volume
andpressurehomeostasisinthecirculatorysystem[6].There
are two transmembrane receptors, NPR-A and NPR-C (a
clearance receptor), which regulate ANP activity [7, 8].
Natriuretic peptides participate in the innate and acquired
immunological response [9]. ANP has been shown to have a
modulating effect on macrophage function and the priming
of polymorphonuclear neutrophils [10].
ANP interferes with both the mitogen-activated protein
kinase (MAPK) network and transcription factors, mainly,
NF-jB[ 11]. Procalcitonin is a 13-kDa prohormone of calci-
tonin. Carboxyl-terminal (CT) peptides (procalcitonin [PCT]
included) have a common origin on the CALC-1 gene on
chromosome 11 [12]. It has been suggested that PCT is a
prototype of hormokine mediators. The deﬁnition of hormo-
kine includes the cytokine-like activity of hormones during
inﬂammation and infection [13]. During the response to
infectiousstimuli,there isonly a limited and transient release
of PCT from macrophages and monocytes. LPS, IL-1b,a n d
TNF-apromote thetissue-wideinductionofCTmRNA,with
the result that PCT is secreted into the circulation.
The half-life of PCT is about 22–35 h [14]. Under
physiological conditions, the level of PCT is lower than
\0.5 ng/ml. It has been stated that PCT should be used as a
diagnostic marker to monitor the course of severe sepsis
and septic shock and antimicrobial therapy [15, 16].
Patients and methods
Patients
Fifty patients with severe sepsis or septic shock admitted to
the Department of Anesthesiology and Intensive Therapy
of Wroclaw Medical University, Poland, were enrolled in
the study. Patients with cardiogenic shock and other acute
circulatory failure not induced by infection were excluded
from the study. Critically ill patients were divided into the
following subgroups: survivors (n = 26) and non-survivors
(n = 24), and severe sepsis (n = 19) and septic shock
(n = 31). The mean age and range (in years) of survivors
and non-survivors was 51 (18–88) and 60.6 (19–91)
(P = 0.057), respectively, and in the severe sepsis and
septic shock groups, they were 47.8 (18–80) and 60.7
(21–91) (P = 0.02), respectively.
The diagnosis of severe sepsis or septic shock was
performed according to the 2001 Consensus Conference
Criteria [3].
Infection was conﬁrmed with microbiological tests,
radiological analysis, and surgical procedures. In ques-
tionable cases, the PCT level was used as conﬁrmation of
the presence of infection.
This study was observational and prospective. Table 1
shows the detailed microbiological results and information
about the sources of infection. The status of clinical
patients was assessed with the Acute Physiology and
Chronic Health Evaluation II (APACHE II) score [17]o n
admission to the ICU, and the extent of multiple organ
failure was evaluated using the Sequential Organ Failure
Assessment (SOFA) score [18] on admission, and on the
2nd, 3rd, and 5th days. All patients were treated according
to accepted standards for severe sepsis and septic shock
(antimicrobial therapy, mechanical ventilation, ﬂuid
resuscitation, vasopressor therapy). All patients had been
receiving empirical antibiotic therapy on admission, which
was modiﬁed according to ongoing microbiological and
laboratory results. The ICU mortality was 48%.
The prognostic and discriminative value of pro-ANP
levels was evaluated in patients diagnosed with severe
sepsis and septic shock.
The control group included 20 healthy volunteers,
comprising 15 females and 5 males (mean age 36.4 years,
range 22–56 years), who were recruited from the ICU staff.
Ethical considerations
The study was approved by the Medical Ethics Committee
of Wroclaw Medical University and informed consent was
obtained from the patients or their legal representatives.
Laboratory measurements
Blood was drawn on admission, and on the 2nd, 3rd, and
5th days. In nine cases, samples from the 5th day were not
available (the patients had died or had been discharged
earlier). Serum was obtained after 15 min of clotting at
room temperature and the blood was centrifuged (10 min,
720g). Serum samples were aliquoted and stored at -80C
to analyze the pro-ANP and PCT concentrations. All
measurements were performed with commercially avail-
able immunoluminometric tests from BRAHMS Diagnos-
tica GmbH (Hennigsdorf, Germany), according to the
manufacturer’s instructions.
Statistical methods
The normality of the distribution was estimated by the
Kolmogorov–Smirnov test. The data were analyzed with a
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two groups. The APACHE II and SOFA score values are
presented as the mean ± standard deviation (SD). A
P value B0.05 was considered to be statistically signiﬁ-
cant. Correlation analysis with continuous data was con-
ducted using Pearson’s correlation test (r).
All analyses were performed using the STATISTICA
data analysis software system, version 9.1 (StatSoft Inc.,
2010, http://www.statsoft.com).
Results
Survivors and non-survivors
As an estimation of the patients’ clinical status, the mean
value of the APACHE II score on admission in survivors
and non-survivors was 18.3 and 27, respectively (Table 2).
The value of the SOFA score was signiﬁcantly lower in
survivors than in non-survivors on all the analyzed days
(Table 2).
The pro-ANP level was signiﬁcantly lower in survivors
than non-survivors on all the analyzed days (Table 3).
Table 1 Source of infection
and microbiological results
Number of patients Site of infection Details Microbiological results
21 Respiratory Lungs Neisseria sp. (1)
Ralstonia mannitolilytica (1)
Enterococcus faecium (2)
Pseudomonas aeruginosa (5)
Staphylococcus aureus (3)
Acinetobacter baumannii (3)
Candida albicans (3)
Unknown (3)
18 Abdominal Peritonitis, pancreatitis,
cholecystitis, UTI
Pseudomonas aeruginosa (1)
Citrobacter freundii (1)
Enterobacter cloacae (1)
Acinetobacter baumannii (1)
Enterococcus faecalis (3)
Staphylococcus aureus (1)
Escherichia coli (1)
Unknown (9)
5 Blood Acinetobacter baumannii (1)
Staphylococcus aureus (1)
Neisseria sp. (1)
Pseudomonas aeruginosa (1)
Candida albicans (1)
6 Other Eye, meningitis,
skin, wound
Neisseria meningitis (1)
Enterobacter cloacae (1)
Pseudomonas aeruginosa (2)
Escherichia coli (1)
Unknown (1)
Table 2 Acute Physiology and Chronic Health Evaluation II
(APACHE II) and Sequential Organ Failure Assessment (SOFA)
scores in survivors and non-survivors
Survivors
(n = 26)
Non-survivors
(n = 24)
P value*
APACHE II1st day 18.3 (8–32) 27 (11–44) 0.000007
SOFA1st day 6.6 (0–14) 11.2 (4–18) 0.00005
SOFA2nd day 5.8 (0–14) 10.6 (3–20) 0.00004
SOFA3rd day 4.8 (0–12) 10.5 (2–20) 0.0001
SOFA5th day 4.2 (0–14) 11.5 (3–19) 0.000007
* P value for differences between survivors and non-survivors
Table 3 Pro-atrial natriuretic peptide (pro-ANP) level (pmol/L)
(median and 95% conﬁdence interval [CI]) in survivors and non-
survivors
Survivors
(n = 26)
Non-survivors
(n = 24)
P value*
pro-ANP1st day 218 (987385) 372 (2777740) 0.008
pro-ANP2nd day 227 (1317402) 472 (2637878) 0.016
pro-ANP3rd day 249 (1557376) 456 (19771,128) 0.043
pro-ANP5th day 158 (1137275) 531 (27271,706) 0.001
* P value for differences between survivors and non-survivors
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analysis of survival, on the day of admission, the cut-off
value was 220.58 pmol/L and area under the curve
(AUC) = 0.72, the sensitivity was 0.917, and the speciﬁcity
was 0.538 (Fig. 1a). On the 2nd therapy day, the cut-off
value was 262.5 pmol/L and AUC = 0.699, the sensitivity
was 0.75, and the speciﬁcity was 0.654 (Fig. 1b). On the 3rd
therapy day, the cut-off value was 409.94 pmol/L and
AUC = 0.673, the sensitivity was 0.591, and the speciﬁcity
was 0.84 (Fig. 1c). On the 5th therapy day, the cut-off value
was 270.34 pmol/L and AUC = 0.789, the sensitivity was
0.789, and the speciﬁcity was 0.76 (Fig. 1d).
Severe sepsis and septic shock
On admission, there was a statistically signiﬁcant differ-
ence in the APACHE II score value of both groups
(P = 0.05). The differences in the SOFA score value were
statistically signiﬁcant in the course of the study, except for
the 5th day (Table 4).
There was no statistically signiﬁcant difference in the
pro-ANP level between the groups (Table 5).
Fig. 1 The receiver operating
characteristic (ROC) curve of
the pro-atrial natriuretic peptide
(pro-ANP) level of survival
analysis on the 1st day with a
cut-off value of 220.58 pmol/L
(area under the curve
[AUC] = 0.72, sensitivity
0.917, and speciﬁcity 0.538) (a);
2nd day with a cut-off value of
262.5 pmol/L (AUC = 0.699,
sensitivity 0.75, and speciﬁcity
0.654) (b); 3rd day with a cut-
off value of 409.94 pmol/L
(AUC = 0.673, sensitivity
0.591, and speciﬁcity 0.84) (c);
5th day with a cut-off value of
270.34 pmol/L (AUC = 0.789,
sensitivity 0.789, and speciﬁcity
0.76) (d)
Table 4 APACHE II and SOFA score in severe sepsis and septic
shock
Severe sepsis
(n = 19)
Septic shock
(n = 31)
P value*
APACHE II1st day 19.5 (8–35) 24.3 (13–44) 0.05
SOFA1st day 6.3 (0–16) 10.4 (5–18) 0.002
SOFA2nd day 5.6 (0–12) 9.6 (2–20) 0.006
SOFA3rd day 5.2 (0–15) 8.7 (1–20) 0.04
SOFA5th day 6.8 (1–19) 8.3 (0–19) 0.6
* P value for differences between severe sepsis and septic shock
Table 5 pro-ANP level (pmol/L) (median and 95% CI) in severe
sepsis and septic shock
Severe sepsis
(n = 19)
Septic shock
(n = 31)
P value*
pro-ANP1st day 295 (1037398) 356 (2297513) 0.27
pro-ANP2nd day 249 (1327584) 369 (2047509) 0.57
pro-ANP3rd day 215 (1427532) 344 (2017592) 0.289
pro-ANP5th day 143 (8771,416) 295 (1797809) 0.18
* P value for differences between severe sepsis and septic shock
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of admission, the cut-off value was 215 pmol/L and
AUC = 0.59, the sensitivity was 0.81, and the speciﬁcity
was 0.47 (Fig. 2a). On the 2nd therapy day, the cut-off
value was 258 pmol/L and AUC = 0.548, the sensitivity
was 0.61, and the speciﬁcity was 0.58 (Fig. 2b). On the 3rd
therapy day, the cut-off value was 162 pmol/L and
AUC = 0.594, the sensitivity was 0.80, and the speciﬁcity
was 0.47 (Fig. 2c). On the 5th therapy day, the cut-off
value was 143 pmol/L and AUC = 0.632, the sensitivity
was 0.81, and the speciﬁcity was 0.53 (Fig. 2d).
There was a strong correlation between the PCT and
pro-ANP levels on admission in non-survivors and in septic
shock patients (r = 0.56, P = 0.007 (Fig. 3a) and
r = 0.43, P = 0.02 (Fig. 3b), respectively).
Discussion
This study was performed in order to determine the prog-
nostic and discriminative properties of pro-ANP in criti-
cally ill patients. In the study, the level of pro-ANP was
lower in survivors than non-survivors, with statistical sig-
niﬁcance reached on all the study days; this was similar to
the results obtained by Vazquez et al. [19]. A decline in the
pro-ANP level was observed starting from the 2nd day in
survivors. Similar results were presented by Morgenthaler
et al. [20] and Boeck et al. [21], but were in contrary to
those of Prucha et al. [22]. In Prucha et al.’s study, the pro-
ANP level did not show any tendencies to increase or
decrease. There was a correlation between the levels of
PCT and pro-ANP on the day of admission in the non-
survivors and septic shock groups. In Morgenthaler et al.
[20] study, the circulating pro-ANP levels showed a similar
increase when categorized on the increasing PCT in all the
study groups.
The highest values of pro-ANP were observed in non-
survivors and was directly associated with the highest
APACHE II and SOFA score results, reﬂecting the clinical
status and progress of multiple organ failure in this group.
There was a correlation between the SOFA value and pro-
ANP level in the non-survivors and septic shock group on
the 1st day. APACHE II and SOFA score values were
lower in the survivors group on admission.
Fig. 2 The ROC curve of the
pro-ANP level of the diagnosis
on the 1st day with a cut-off
value of 215 pmol/L
(AUC = 0.59, sensitivity 0.81,
and speciﬁcity 0.47) (a); 2nd
day with a cut-off value of
258 pmol/L (AUC = 0.548,
sensitivity 0.61, and speciﬁcity
0.58) (b); 3rd day with a cut-off
value of 162 pmol/L
(AUC = 0.594, sensitivity 0.80,
and speciﬁcity 0.47) (c); 5th day
with a cut-off value of
143 pmol/L (AUC = 0.632,
sensitivity 0.81, and speciﬁcity
0.53) (d)
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sepsis and septic shock subgroups, did not reﬂect statistical
signiﬁcance in the APACHE II and SOFA score results.
These results were similar to Morgenthaler et al. study
[20], where there were no statistically signiﬁcant differ-
ences in the pro-ANP levels between the severe sepsis and
septic shock groups. All those results indicate that pro-
ANP measured in severe sepsis or septic shock patients is a
valuable prognostic biomarker without diagnostic and
discriminative value, which is in contrast to PCT [23, 24].
Boeck et al. [21] found that patients with the highest pro-
ANP quartile at ventilator-associated pneumonia (VAP)
onset were at increased risk for death, and pro-ANP was
identiﬁed as the best predictor of survival, followed by the
SOFA and Simpliﬁed Acute Physiology Score (SAPS) II
values.
Morgenthaler et al. [20] did not observe any signiﬁcant
differences in the pro-ANP levels between survivors and
non-survivors with no infection. This suggests that pro-
inﬂammatory factors like TNF-a and IL-6 have a greater
inﬂuence on the release of pro-ANP than the hemodynamic
changes linked to circulatory dysfunction that is essential
for severe sepsis or septic shock [25].
The question as to why the level of pro-ANP is similar
in such clinically differentiated conditions like severe
sepsis and septic shock is still open for discussion and
further study.
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